Johnson and Johnson buys FemRx in expansion of women's health business
This article was originally published in Clinica
Executive Summary
Johnson & Johnson is to buy women's health company FemRx for around $22 million in cash. The move will boost J&J's women's health business, which makes products for the treatment of a diversified range of gynaecological and urological disorders. FemRx has had a difficult year, beginning with job cuts and, more recently, the threat of delisting from the Nasdaq national market.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.